Eric Lefkofsky Sells 166,250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the firm’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $46.38, for a total value of $7,710,675.00. Following the completion of the sale, the chief executive officer directly owned 8,875,033 shares of the company’s stock, valued at approximately $411,624,030.54. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Tempus AI Stock Performance

NASDAQ:TEM opened at $42.62 on Friday. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. Tempus AI, Inc. has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The stock has a market cap of $7.62 billion, a PE ratio of -30.23 and a beta of 5.29. The firm’s fifty day simple moving average is $55.11 and its 200-day simple moving average is $69.73.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its holdings in shares of Tempus AI by 201.2% in the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after purchasing an additional 17,359 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Tempus AI in the first quarter valued at approximately $116,000. Cetera Investment Advisers increased its stake in shares of Tempus AI by 18.8% during the 2nd quarter. Cetera Investment Advisers now owns 32,417 shares of the company’s stock worth $2,060,000 after purchasing an additional 5,123 shares in the last quarter. Swiss National Bank acquired a new position in shares of Tempus AI during the 2nd quarter worth approximately $9,175,000. Finally, Legal & General Group Plc raised its position in shares of Tempus AI by 24.4% during the 2nd quarter. Legal & General Group Plc now owns 450,645 shares of the company’s stock worth $28,634,000 after purchasing an additional 88,373 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ARK Invest (Cathie Wood) trimmed positions in Meta and Nvidia and added to Tempus, signaling renewed institutional demand and attention that can support liquidity and investor interest. Cathie Wood’s ARK sells Meta and Nvidia stocks, buys Tempus AI
• Positive Sentiment: Tempus announced a collaboration with Daiichi Sankyo focused on ADC clinical development, reinforcing commercial partnerships in oncology that support longer‑term revenue and platform use cases. Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
• Positive Sentiment: Analysts maintain constructive views — Tempus has a consensus “Moderate Buy” rating, which may help underwrite investor confidence after recent volatility. Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Coverage pieces (Zacks/Yahoo) highlight a string of 2026 collaborations and strategic initiatives that expand Tempus’s AI/diagnostics reach; these are generally positive but are longer‑term catalysts rather than immediate earnings drivers. Tempus AI Reinforces Market Position With Collaborations in 2026
• Negative Sentiment: Zacks notes the stock is down materially since the last earnings report (about a 12.9% decline), pointing to investor concern about recent results/forward outlook and heightening short‑term selling pressure. Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: Technical/volatility pressures: the stock is trading below its 50‑ and 200‑day moving averages and has a high beta, which can amplify downside moves while investors reassess fundamentals and partnership monetization timelines.

Analyst Ratings Changes

Several brokerages have weighed in on TEM. JPMorgan Chase & Co. lowered their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. BTIG Research lowered their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Wednesday, March 11th. Finally, HC Wainwright lifted their price objective on Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and an average price target of $78.62.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.